BACKGROUND: Oral anticoagulation therapy (OAT) prevents ischaemic incidents in patients with atrial fibrillation (AF). CHA2DS2-VASc risk score of ≥2 points in men and ≥3 in women is a class I indication for OAT. OAT should also be considered as a prevention of thromboembolism in AF men with a CHA2DS2-VASc score of 1 point and women with 2 points, but the class of recommendation is lower (IIa). This study aims to assess the occurrence of left atrial appendage thrombus (LAAT) and risk factors of its formation in patients with lower class recommendation to oral antiocoagulation treatment. METHODS: The study group consisted of 1,858 patients: 555 patients with class IIa indication to OAT (IIa group) and 1,303 patients with class I indication as a control group (I group). Patients were admitted to three cardiology departments. All subjects underwent transoesophageal echocardiography. RESULTS: The incidence of LAAT was comparable in both IIa and I group: LAAT was confirmed in 30 (5.4%) subjects of IIa group and in 77 (5.9%) of I group. The prevalence of LAAT in IIa group was higher on treatment with VKAs (in comparison to NOACs) (8.4% vs. 3.4%, P=0.010), and lower in case of paroxysmal AF (in comparison to non-paroxysmal AF) (2.4% vs. 9.8%, P=0.0002). Multivariate logistic regression revealed the following variables as the independent predictors of LAAT in IIa group: treatment with VKAs (OR 2.99, 95% CI: 1.33-6.69; P=0.007), paroxysmal AF (OR 0.26, 95% CI: 0.11-0.62; P=0.002) and eGFR <60 mL/min/1.73 m2 (OR 3.19, 95% CI: 1.42-7.16; P=0.005). CONCLUSIONS: The prevalence of LAAT in AF patients with lower class (IIa) recommendation to anticoagulants was comparable to higher (I). Treatment with VKAs, along with non-paroxysmal type of AF and eGFR <60 mL/min/1.72 m2 were identified as the strongest predictors of LAAT in IIa group. 2020 Cardiovascular Diagnosis and Therapy. All rights reserved.
BACKGROUND: Oral anticoagulation therapy (OAT) prevents ischaemic incidents in patients with atrial fibrillation (AF). CHA2DS2-VASc risk score of ≥2 points in men and ≥3 in women is a class I indication for OAT. OAT should also be considered as a prevention of thromboembolism in AF men with a CHA2DS2-VASc score of 1 point and women with 2 points, but the class of recommendation is lower (IIa). This study aims to assess the occurrence of left atrial appendage thrombus (LAAT) and risk factors of its formation in patients with lower class recommendation to oral antiocoagulation treatment. METHODS: The study group consisted of 1,858 patients: 555 patients with class IIa indication to OAT (IIa group) and 1,303 patients with class I indication as a control group (I group). Patients were admitted to three cardiology departments. All subjects underwent transoesophageal echocardiography. RESULTS: The incidence of LAAT was comparable in both IIa and I group: LAAT was confirmed in 30 (5.4%) subjects of IIa group and in 77 (5.9%) of I group. The prevalence of LAAT in IIa group was higher on treatment with VKAs (in comparison to NOACs) (8.4% vs. 3.4%, P=0.010), and lower in case of paroxysmal AF (in comparison to non-paroxysmal AF) (2.4% vs. 9.8%, P=0.0002). Multivariate logistic regression revealed the following variables as the independent predictors of LAAT in IIa group: treatment with VKAs (OR 2.99, 95% CI: 1.33-6.69; P=0.007), paroxysmal AF (OR 0.26, 95% CI: 0.11-0.62; P=0.002) and eGFR <60 mL/min/1.73 m2 (OR 3.19, 95% CI: 1.42-7.16; P=0.005). CONCLUSIONS: The prevalence of LAAT in AF patients with lower class (IIa) recommendation to anticoagulants was comparable to higher (I). Treatment with VKAs, along with non-paroxysmal type of AF and eGFR <60 mL/min/1.72 m2 were identified as the strongest predictors of LAAT in IIa group. 2020 Cardiovascular Diagnosis and Therapy. All rights reserved.
Entities:
Keywords:
Left atrial thrombus; atrial fibrillation; lower class recommendation; oral anticoagulants
Authors: Pamela K Mason; Douglas E Lake; John P DiMarco; John D Ferguson; J Michael Mangrum; Kenneth Bilchick; Liza P Moorman; J Randall Moorman Journal: Am J Med Date: 2012-04-11 Impact factor: 4.965
Authors: Jonathan P Piccini; Susanna R Stevens; YuChiao Chang; Daniel E Singer; Yuliya Lokhnygina; Alan S Go; Manesh R Patel; Kenneth W Mahaffey; Jonathan L Halperin; Günter Breithardt; Graeme J Hankey; Werner Hacke; Richard C Becker; Christopher C Nessel; Keith A A Fox; Robert M Califf Journal: Circulation Date: 2012-12-03 Impact factor: 29.690
Authors: Gregory Y H Lip; Cécile Laroche; Popescu Mircea Ioachim; Lars Hvilsted Rasmussen; Laura Vitali-Serdoz; Lucian Petrescu; Dan Darabantiu; Harry J G M Crijns; Paulus Kirchhof; Panos Vardas; Luigi Tavazzi; Aldo P Maggioni; Giuseppe Boriani Journal: Eur Heart J Date: 2014-08-31 Impact factor: 29.983
Authors: Wael Alqarawi; David H Birnie; Stewart Spence; F Daniel Ramirez; Calum J Redpath; Robert Lemery; Girish M Nair; Pablo B Nery; Darryl R Davis; Martin S Green; Luc Beauchesne; Kwan Chan; Kathryn Ascah; Ian Burwash; Mouhannad M Sadek Journal: Europace Date: 2019-01-01 Impact factor: 5.214
Authors: Paulus Kirchhof; Bettina Ammentorp; Harald Darius; Raffaele De Caterina; Jean-Yves Le Heuzey; Richard John Schilling; Josef Schmitt; Jose Luis Zamorano Journal: Europace Date: 2013-10-01 Impact factor: 5.214
Authors: Beata Uziębło-Życzkowska; Paweł Krzesiński; Małgorzata Maciorowska; Iwona Gorczyca; Olga Jelonek; Maciej Wójcik; Robert Błaszczyk; Agnieszka Kapłon-Cieślicka; Monika Gawałko; Tomasz Tokarek; Renata Rajtar-Salwa; Jacek Bil; Michał Wojewódzki; Anna Szpotowicz; Małgorzata Krzciuk; Janusz Bednarski; Elwira Bakuła-Ostalska; Anna Tomaszuk-Kazberuk; Anna Szyszkowska; Marcin Wełnicki; Artur Mamcarz; Beata Wożakowska-Kapłon Journal: Cardiovasc Diagn Ther Date: 2021-02